By Brad Sorensen, CFA
OTC:NRXBF | TSX:NRX.V
READ THE FULL NRXBF RESEARCH REPORT
NurExone (OTC:NRXBF) (TSX:NRX.V) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ExoPTEN may be able to treat. On that latter point, the company, late last year, announced some preclinical test results that have the potential to benefit thousands of patients and increase the value of NRXBF to investors. Additionally, the company recently released independent test results that showed its exosomes vastly outperformed a recognized commercial industry standard in areas that strongly support key healing tasks. Lastly, the company was awarded a US patent for its proprietary process for producing exosomes.
Before getting into these exciting results, we briefly want to touch on the 2Q financial results recently released. These results show an improved cash position, a continued clean balance sheet with low liabilities, and a commitment to controlling expenses—continuing the good management practices we have seen with NurExone’s throughout their history.
These financials and the test results further our belief in the ExoPTEN product and reinforce our belief that it is a potential breakthrough treatment, and investors should start paying attention. The CEO of the US subsidiary summarized the results and illustrates why we are enthusiastic about NurExone. Mr. Jacob Licht said, “This data confirms that the naïve exosomes that will be manufactured by our U.S. subsidiary will carry a strong regenerative and therapeutic punch. Delivering more than twice the wound-healing signals than the industry benchmark suggests applications in aesthetic skin rejuvenation, wound care, and orthopedic tissue repair. As we scale production in the United States with our patent-pending 3D production process, ExoTOP (the US subsidiary) is expected to generate multiple revenue streams and provide high-performance exosomes to partners across regenerative medicine.”
It's also important to note that these exosomes came from NurExone’s own cell bank, and are under strict environmental controls and are reproducible at the same high-performance level. The unique nature of producing the exosomes was validated recently when the US Patent and Trademark Office issued a Notice of Allowance for a patent covering that process. This adds to the international patents already in place and strengthens the company’s intellectual property protection.
Company management also recently announced that its preclinical study on ExoPTEN for the treatment of spinal cord injuries demonstrated that higher doses of the treatment led to regained motor function after a spinal cord injury. The study was conducted on small animals, which were given differing doses of ExoPTEN on the day of spinal compression surgery. The results show that 100% of animals treated with the higher dose regained walking ability in both front and hind legs, while only 1 out of 6 of the untreated animals achieved that milestone. This is an exciting result and provides further proof of the potential for ExoPTEN to be game-changing treatment.
To further the process, the company plans to initiate a Phase 1/2a clinical trial in the area of acute spinal cord injuries for ExoPTEN in 2026. Management detailed the study plans as involving adult patients with traumatic spinal cord injuries between spinal levels C5 and T10. Those patients will be treated within 3 to 7 days post-injury. This marks a significant step forward for the company in our view, and, given the preclinical results that we have outlined, we expect the trial to yield exciting results.
As a reminder, spinal injuries aren’t the only condition being targeted. Company management recently announced significant findings from an expanded study of ExoPTEN for repairing optic nerve damage. Using a rodent model of optic nerve crush to simulate damage associated with conditions such as glaucoma. Analysis of the data showed clear recovery of signal transmission in treated eyes compared to untreated controls, which showed no significant response.
According to the company, the study also showed significantly enhanced survival of retinal ganglion cells, which are key neurons responsible for transmitting visual information to the brain.
We were also encouraged to hear comments from the lead investigator at the Goldschleger Eye Institute, part of a top hospital the company is collaborating with, when Dr. Ifat Sher said, “The results from this expanded study are extremely encouraging. ExoPTEN demonstrates potential as a treatment that restores functionality and offers neuroprotection. The study shows clear signal recovery, healthier optic nerve structures, and preserved retinal ganglion cells. These results suggest that ExoPTEN could fundamentally change how we approach conditions like glaucoma and optic nerve trauma.”
With a market size of approximately $5.5 billion currently, based on estimates cited by the company, and a projected growth rate of over 8% annually, the potential for this treatment is extensive and is an exciting addition to the company’s portfolio.
The company’s ExoPTEN therapy has received the Orphan Medicinal Product Designation by the European Medicines Agency (EMA). According to the company, the EMA’s Orphan Medicinal Product Designation offers incentives, including ten years of market exclusivity upon approval, access to grants and incentives from the European Commission and member states. Additionally, the company may benefit from free or reduced-cost scientific advice and assistance with clinical trial design, which can streamline the regulatory process and reduce development costs. Lastly, some European Union countries also provide tax credits and other financial incentives to support orphan drug development.
As we’ve noted before, the company received the Orphan Drug Designation for ExoPTEN in 2023 from the FDA in the United States. This designation was created by the FDA, which noted that supporting the development and evaluation of new treatments for rare diseases is a key priority for the agency. The FDA has authority to grant orphan drug designation to a drug or biological product to prevent, diagnose, or treat a rare disease or condition. Orphan drug designation qualifies sponsors for incentives, including:
- Tax credits for qualified clinical trials
- Exemption from user fees
- Potential seven years of market exclusivity after approval
It was earlier test results from the use of ExoPTEN that sparked our enthusiasm for the company, because the initial test results are, in our view, truly remarkable. This isn’t a potential treatment that was arrived at quickly or easily, as research began at the University level and was conducted between January 2017 and May 2020, including testing the use of intranasal administration of exosomes driven from mesenchymal stem cells loaded with siRNA (a process that is described in more detail below). Testing targeted a complete spinal cord transection in rats, which is the strictest animal testing model, successfully demonstrating significant functional recovery. The company notes that the technology is successfully proven in additional preclinical studies, demonstrating that intranasal administration of ExoPTEN led to significant motor improvement, sensory recovery, and faster urinary reflex restoration. As mentioned, the research began at the University level, and the Company has been granted an exclusive worldwide license from the Technion and Tel Aviv University, which includes a patent application, to develop and commercialize the technology. In addition, the Company has developed its own intellectual property and now has five families of patents.
We continue to be enthusiastic about the prospects for NurExone and suggest that US investors follow the Canadians and look into NRXBF. We urge investors with a higher risk tolerance to take a look at NRXBF and consider whether this compelling story may be of interest.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.